Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acasti Pharma Temettü

Temettü kriter kontrolleri 0/6

Acasti Pharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.13
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ACST şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ACST şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Acasti Pharma Piyasaya Karşı Temettü Getirisi

ACST temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ACST)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (ACST) (3 yıla kadar)	n/a

Önemli Temettü: ACST şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ACST şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ACST şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ACST herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Acasti Pharma Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Acasti Pharma Inc. Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc., Annual General Meeting, Sep 30, 2024

Acasti Pharma Inc. Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-On Safety Trial

New major risk - Revenue and earnings growth

Acasti Pharma Inc. to Attend BIO International Convention 2024

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

New major risk - Revenue and earnings growth

Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial

Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Acasti Pharma Inc. Announces Board Changes

Independent Chairman recently bought US$1.2m worth of stock

Acasti Pharma Inc. announced that it has received $7.499388 million in funding from S S Pharma Llc, Shore Pharma Llc

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Acasti Pharma Announces 1-For-6 Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Continued Listing Requirement of the Nasdaq Capital Market

Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. Announces Scientific Advisory Board Appointments

Forecast to breakeven in 2024

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025

Acasti Pharma Inc. to Report Q3, 2023 Results on Feb 14, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma Inc. Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Forecast to breakeven in 2024

High number of new and inexperienced directors

Acasti Pharma Inc. to Report Q2, 2023 Results on Nov 14, 2022

Acasti Pharma Inc. Announces Board Changes

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, Drug Candidate for the Treatment of Ataxia Telangiectasia

Acasti Pharma GAAP EPS of -$0.10

Acasti Pharma Inc. to Report Q1, 2023 Results on Aug 11, 2022

Acasti Pharma Inc., Annual General Meeting, Sep 28, 2022

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Less than half of directors are independent

Less than half of directors are independent

Acasti Pharma Inc. Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma Inc. Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, its Lead Drug Candidate for Treatment of Subarachnoid Hemorrhage

Acasti Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Insufficient new directors

Acasti Pharma Inc. (TSXV:ACST) completed the acquisition of Grace Therapeutics, Inc.

Forecast breakeven pushed back to 2024

Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

Acasti Pharma Inc. (TSXV:ACST) entered into a definitive agreement to acquire Grace Therapeutics, Inc. for $71.4 million.

Acasti inks deal for Grace Therapeutics, shares surge

Earnings miss expectations

New 90-day high: US$0.90

New 90-day high: US$0.57

New 90-day high: US$0.43

Acasti Pharma issues clarification on trading activity

New 90-day high: US$0.29

Acasti Pharma Inc. Announces Resignation of Brian Groch as Chief Commercial Officer, Effective December 31, 2020

Acasti Pharma EPS in-line

Acasti Pharma Inc. Announces Executive Changes

New 90-day low - US$0.24

Acasti Pharma Inc. Auditor Raises 'Going Concern' Doubt

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin